Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 301–400 of 4,108
FRAX and fracture prediction without bone mineral density
Kanis, J. A., Harvey, N. C., Johansson, H., Odén, A., Leslie, W. D., & McCloskey, E. V. (2015) · Climacteric · doi:10.3109/13697137.2015.1092342 · Cited by 90
Lee, J.-S., Lee, S., Jang, S., et al. (2013) · Endocrinology and Metabolism · doi:10.3803/enm.2013.28.3.180 · Cited by 81
Establishing a Fracture Liaison Service: An Orthopaedic Approach
Miller, A. N., Lake, A. F., & Emory, C. L. (2015) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.n.00957 · Cited by 82
Boschitsch, E., Durchschlag, E., & Dimai, H. P. (2017) · Climacteric · doi:10.1080/13697137.2017.1282452 · Cited by 94
Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta‐Analysis
Nayak, S., & Greenspan, S. L. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14668 · Cited by 79
Choi, H. K., Kim, G.-J., Yoo, H.-S., Song, D. H., Chung, K., Lee, K.-J., Koo, Y. T., & An, J. H. (2019) · Nutrients · doi:10.3390/nu11030506 · Cited by 94
Vitamin D regulation of adipogenesis and adipose tissue functions
Nimitphong, H., Park, E., & Lee, M. (2020) · Nutrition Research and Practice · doi:10.4162/nrp.2020.14.6.553 · Cited by 92
The effects of caffeine on bone mineral density and fracture risk
Berman, N., Honig, S., Cronstein, B. N., & Pillinger, M. H. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05972-w · Cited by 92
“Osteoporosis affects a large percentage of the population, and its prevalence is anticipated to increase further as the population ages [2].”
BackgroundOsteoporosis: An Update on Screening, Diagnosis, Evaluation, and Treatment
Sabri, S. A., Chavarria, J. C., Ackert‐Bicknell, C. L., Swanson, C. M., & Burger, E. L. (2022) · Orthopedics · doi:10.3928/01477447-20220719-03 · Cited by 103
A comprehensive review of denosumab for bone metastasis in patients with solid tumors
Gül, G., Şendur, M. A. N., Aksoy, S., Sever, A. R., & Altundağ, K. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1105795 · Cited by 88
Gajic‐Veljanoski, O., Phua, C. W. W., Shah, P. S., & Cheung, A. M. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3603-8 · Cited by 84
Aboarrage, A. M., Teixeira, C. V. L. S., dos Santos, R. N., Machado, A. F., Evangelista, A. L., Rica, R. L., Alonso, A. C., Barroso, J. A., Serra, A. J., Baker, J. S., et al. (2018) · Rejuvenation Research · doi:10.1089/rej.2018.2069 · Cited by 93
Marinova, M., Edon, B., Wolter, K., Katsimbari, B., Schild, H. H., & Strunk, H. M. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1074892 · Cited by 84
Watts, N. B., Ettinger, B. B., & LeBoff, M. S. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090402 · Cited by 86
Self-citationLittle, E. A., Presseau, J., & Eccles, M. (2015) · Implementation Science · doi:10.1186/s13012-015-0280-7 · Cited by 91
Söreskog, E., Ström, O., Spångéus, A., Åkesson, K., Borgström, F., Banefelt, J., Tóth, E., Libanati, C. R., & Charokopou, M. (2020) · Bone · doi:10.1016/j.bone.2020.115286 · Cited by 91
Osteoporosis and fractures in rheumatoid arthritis
Wysham, K. D., Baker, J. F., & Shoback, D. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000789 · Cited by 87
“The NOF guideline supports BMD screening in all patients with RA aged 50 years and older [54].”
BackgroundMethodManagements of osteoporotic vertebral compression fractures: A narrative review
Patel, D., Liu, J., & Ebraheim, N. A. (2022) · World Journal of Orthopedics · doi:10.5312/wjo.v13.i6.564 · Cited by 92
Khatod, M. X., Inacio, M. C. S., Dell, R. M., Bini, S. A., Paxton, E. W., & Namba, R. S. (2015) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-015-4263-4 · Cited by 88
LeBlanc, A., Wang, A. T., Wyatt, K., Branda, M. E., Shah, N. D., Van Houten, H., Pencille, L., Wermers, R., & Montori, V. M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128063 · Cited by 77
Autophagy as a target for glucocorticoid-induced osteoporosis therapy
Shen, G., Ren, H. J., Shang, Q., Qiu, T., Yu, X., Zhang, Z., Huang, J., Zhao, W., Zhang, Y., Liang, D., et al. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2776-1 · Cited by 80
Orthopedic Surgery and the Geriatric Patient
Greenstein, A. S., & Gorczyca, J. T. (2018) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2018.08.007 · Cited by 88
The 2018 Guidelines for the diagnosis and treatment of osteoporosis in Greece
Makras, P., Anastasilakis, A. D., Antypas, G. D., Chronopoulos, E., Kaskani, E., Matsouka, A., Patrikos, D., Stathopoulos, K. D., Tournis, S., Trovas, G., et al. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0584-3 · Cited by 80
Martineau, P., Leslie, W. D., Johansson, H., Odén, A., McCloskey, E. V., Hans, D. B., & Kanis, J. А. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3124 · Cited by 77
Derkatch, S., Kirby, C. K., Kimelman, D., Jozani, M. J., Davidson, J. M., & Leslie, W. D. (2019) · Radiology · doi:10.1148/radiol.2019190201 · Cited by 77
Forgetta, V., Keller‐Baruch, J., Forest, M., Durand, A., Bhatnagar, S., Kemp, J. P., Nethander, M., Evans, D. S., Morris, J. A., Kiel, D. P., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003152 · Cited by 80
“In the absence of an international consensus on fracture risk screening [2,4,5,30], we chose to use the assessment and management clinical algorithm developed by NOGG [3], since a screening program similar to the NOGG screening strategy is supported by randomized controlled trial evidence [9].”
BackgroundMethodCalcium Supplements and Risk of Cardiovascular Disease: A Meta-Analysis of Clinical Trials
Myung, S.-K., Kim, H.-B., Lee, Y.-J., Choi, Y.-J., & Oh, S.-W. (2021) · Nutrients · doi:10.3390/nu13020368 · Cited by 76
Osteoporosis in Cervical Spine Surgery
Guzman, J. Z., Feldman, Z. M., McAnany, S. J., Hecht, A. C., Qureshi, S. A., & Cho, S. K.-W. (2015) · Spine · doi:10.1097/brs.0000000000001347 · Cited by 80
Advances in imaging approaches to fracture risk evaluation
Manhard, M. K., Nyman, J. S., & Does, M. D. (2016) · Translational research · doi:10.1016/j.trsl.2016.09.006 · Cited by 84
Recknor, C. P., Recker, R. R., Benson, C. T., Robins, D. A., Chiang, A. Y., Alam, J., Hu, L., Matsumoto, T., Sowa, H., Sloan, J. H., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2489 · Cited by 74
Diabetes, bone and glucose-lowering agents: clinical outcomes
Schwartz, A. V. (2017) · Diabetologia · doi:10.1007/s00125-017-4283-6 · Cited by 78
Ganji, R., Moghbeli, M., Sadeghi, R., Bayat, G., & Ganji, A. (2019) · Nutrition Journal · doi:10.1186/s12937-019-0434-6 · Cited by 79
Wrist Fracture and Risk of Subsequent Fracture: Findings from the Women's Health Initiative Study
Crandall, C. J., Hovey, K. M., Cauley, J. A., Andrews, C., Curtis, J. R., Wactawski‐Wende, J., Wright, N. C., Li, W., & LeBoff, M. S. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2559 · Cited by 78
Self-citationBellavia, D., Costa, V., Luca, A. D., Maglio, M., Pagani, S., Fini, M., & Giavaresi, G. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0331-2 · Cited by 98
Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis
Naranjo, A., Fontecha, P. D. D. C., Acín, M. P. A., Rodríguez, L. M. A., Casado, E., Castañeda, S., Aresté, J. F., Gifre, L., Vaquero, C. G., Candelas, G., et al. (2018) · Reumatología Clínica · doi:10.1016/j.reuma.2018.09.004 · Cited by 104
Spaceflight-Induced Bone Tissue Changes that Affect Bone Quality and Increase Fracture Risk
Coulombe, J. C., Senwar, B., & Ferguson, V. L. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00540-y · Cited by 82
Wang, Y., Zhao, R. Z., Gu, Z., Dong, C., Guo, G., & Li, L. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05360-w · Cited by 83
“All BPs (except for etidronate) are widely used in daily clinical practice, with different administration methods and frequency [44].”
BackgroundManagement of Osteoporosis and Spinal Fractures: Contemporary Guidelines and Evolving Paradigms
Imamudeen, N., Basheer, A., Iqbal, A. M., Manjila, N., Haroon, N. N., & Manjila, S. V. (2022) · Clinical Medicine & Research · doi:10.3121/cmr.2021.1612 · Cited by 88
Increased fracture rate in women with breast cancer: a review of the hidden risk
Body, J. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-384 · Cited by 72
Jiang, X., Gruner, M., Trémollières, F., Pluskiewicz, W., Sornay‐Rendu, E., Adamczyk, P., & Schnatz, P. F. (2017) · Bone · doi:10.1016/j.bone.2017.02.008 · Cited by 81
Cystic fibrosis bone disease treatment: Current knowledge and future directions
Putman, M. S., Anabtawi, A., Le, T. N. H., Tangpricha, V., & Sermet‐Gaudelus, I. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.08.017 · Cited by 78
Wu, W., Xiao, Z., Chen, Y., Deng, Y., Zeng, D., Liu, Y., Huang, F., Wang, J., Liu, Y., Bellanti, J. A., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.003 · Cited by 75
“DISCUSSION There are over 200 million individuals suffering from osteoporosis throughout the world and more than one-third of menopausal women who experience osteoporotic fractures after the age of 50.(31) Current drug treatment regimens consist mainly of antiresorptive agents, which are unable to stimulate new bone f…”
BackgroundTreat-to-target for Osteoporosis: Is Now the Time?
Lewiecki, E. M., Cummings, S. R., & Cosman, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3680 · Cited by 72
Self-citationGriebeler, M. L., Kearns, A. E., Ryu, E., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3964 · Cited by 72
Zamani, M., Zamani, V., Heidari, B., Parsian, H., & Esmaeilnejad-Ganji, S. M. (2018) · Archives of Osteoporosis · doi:10.1007/s11657-018-0540-7 · Cited by 80
Johansson, H., Kanis, J. A., Odén, A., Leslie, W. D., Fujiwara, S., Glüer, C. C., Kroger, H., LaCroix, A. Z., Lau, E., Melton, L. J., et al. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9911-2 · Cited by 71
Datta, M., & Schwartz, G. G. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0051 · Cited by 75
ACOG Clinical Practice Guideline No. 2: Management of Postmenopausal Osteoporosis
Yeap, S. S., Hew, F., & Chan, S.-P. (2022) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004730 · Cited by 81
Batoon, L., Millard, S. M., Raggatt, L. J., Wu, A., Kaur, S., Sun, L. W. H., Williams, K., Sandrock, C. J., Ng, P. Y., Irvine, K. M., et al. (2021) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4413 · Cited by 78
Modifiable risk factors for bone health & fragility fractures
Wilson-Barnes, S., Lanham-New, S. A., & Lambert, H. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101758 · Cited by 96
Monaco, M. D., Castiglioni, C., Toma, E. D., Gardin, L., Giordano, S., & Tappero, R. (2015) · Medicine · doi:10.1097/md.0000000000000542 · Cited by 81
Dielectric properties of bones for the monitoring of osteoporosis
Amin, B., Elahi, A., Shahzad, A., Porter, E., McDermott, B., & O’Halloran, M. (2018) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-018-1887-z · Cited by 70
Osteoporosis and paleopathology: a review.
Curate, F. (2014) · PubMed · doi:10.4436/jass.92003 · Cited by 99
Murray, T. É., Williams, D., & Lee, M. J. (2017) · Abdominal Radiology · doi:10.1007/s00261-017-1124-5 · Cited by 69
“Adults with low BMD should be instructed to ensure a daily intake of 1000–1200 mg of calcium and ‡600 international units of vitamin D [27, 31].”
BackgroundStages of sarcopenia, bone mineral density, and the prevalence of osteoporosis in older women
Lima, R. M., de Oliveira, R. J., Lemos, R. R., Neri, S. G. R., & Gadelha, A. B. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0591-4 · Cited by 76
Risk of Subsequent Fractures in Postmenopausal Women After Nontraumatic vs Traumatic Fractures
Crandall, C. J., Larson, J. C., LaCroix, A. Z., Robbins, J. A., Wactawski‐Wende, J., Johnson, K., Sattari, M., Stone, K. L., Weitlauf, J. C., Gure, T. R., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2617 · Cited by 73
Mikula, A. L., Lakomkin, N., Pennington, Z. A., et al. (2022) · Journal of Neurosurgery Spine · doi:10.3171/2022.3.spine22197 · Cited by 69
Low Vitamin D Status: Definition, Prevalence, Consequences, and Correction
Binkley, N., Ramamurthy, R., & Krueger, D. C. (2012) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2012.03.006 · Cited by 76
Diagnosis and management of osteoporosis in the older senior
Vondracek, S. F., & Linnebur, S. A. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4965 · Cited by 87
Curtis, E., Moon, R. J., Harvey, N. C., & Cooper, C. C. (2017) · International Journal of Orthopaedic and Trauma Nursing · doi:10.1016/j.ijotn.2017.04.004 · Cited by 89
Diretrizes brasileiras para o diagnóstico e tratamento da osteoporose em mulheres na pós‐menopausa
Radominski, S., Bernardo, W. M., de Paula, A. P., Albergaria, B., Moreira, C., Fernandes, C. E., Castro, C. H. D. M., Zerbini, C. A. F., Domiciano, D. S., de Mendonça, L. M. C., et al. (2017) · Revista Brasileira de Reumatologia · doi:10.1016/j.rbr.2017.06.001 · Cited by 197
Bone-Muscle Mutual Interactions
Lara-Castillo, N., & Johnson, M. L. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00602-6 · Cited by 73
Prevalence of osteoporosis among the elderly population of Iran
Fahimfar, N., Noorali, S., Yousefi, S., Gharibzadeh, S., Shafiee, G., Panahi, N., Sanjari, M., Heshmat, R., Sharifi, F., Mehrdad, N., et al. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-020-00872-8 · Cited by 81
Incidence of second hip fracture and compliant use of bisphosphonate
Lee, Y., Ha, Y., Yoon, B.-H., & Koo, K. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2250-0 · Cited by 68
Fischer, V., Haffner‐Luntzer, M., Prystaz, K., Scheidt, A. V., Busse, B., Schinke, T., Amling, M., & Ignatius, A. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-07511-2 · Cited by 71
Management of Osteoporosis in Men: A Narrative Review
Vescini, F., Chiodini, I., Falchetti, A., Palermo, A., Salcuni, A. S., Bonadonna, S., Geronimo, V. D., Cesareo, R., Giovanelli, L., Brigo, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413640 · Cited by 82
“The National Osteoporosis Foundation (NOF), the Endocrine Society, as well as the Italian Society for Osteoporosis, Mineral Metabolism, and Bone Diseases (SIOMMMS) recommend the use of a male-specific reference range [49,50,72], while the ISCD and the International Osteoporosis Foundation (IOF) recommend the calculati…”
BackgroundMiller, P. D., Hattersley, G., Lau, E., Fitzpatrick, L. A., Harris, A. G., Williams, G. C., Hu, M.-Y. Y., Riis, B. J., Russo, L. A. T., & Christiansen, C. (2018) · Bone · doi:10.1016/j.bone.2018.10.015 · Cited by 66
Haffer, H. P. H., Muellner, M., Chiapparelli, E. A., Moser, M., Dodo, Y., Zhu, J., Shue, J., Sama, A. A., Cammisa, F. P., Girardi, F. P., et al. (2022) · The Spine Journal · doi:10.1016/j.spinee.2022.05.008 · Cited by 72
For the Osteoporotic Fractures in Men (MrOS) Study Group, Fink, H. A., Litwack‐Harrison, S., Taylor, B. C., Bauer, D. C., ORWOLL, E. S., Lee, C. G., Barrett-Connor, E. L., Schousboe, J. T., Kado, D. M., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3356-y · Cited by 64
Screening and Treatment of Osteoporosis After Hip Fracture: Comparison of Sex and Race
Antonelli, M. J., Einstadter, D., & Magrey, M. (2014) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2014.01.009 · Cited by 69
Association of osteoporosis and bone medication with the periodontal condition in elderly women
Penoni, D. C., Torres, S. R., Farias, M. L. F., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3437-y · Cited by 66
Leslie, W. D., Shevroja, E., Johansson, H., McCloskey, E. V., Harvey, N. C., Kanis, J. А., & Hans, D. B. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4405-0 · Cited by 68
Ross, E. L., Zuromski, K. L., Reis, B. Y., Nock, M. K., Kessler, R. C., & Smoller, J. W. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0089 · Cited by 65
The biological effects of tocotrienol on bone: a review on evidence from rodent models
Chin, K., & Ima-Nirwana, S. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s79660 · Cited by 70
Kawalilak, C. E., Johnston, J. D., Olszynski, W. P., & Kontulainen, S. A. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2719-0 · Cited by 72
Estimation and projection about the standardized prevalence of osteoporosis in mainland China
Cui, Z., Meng, X., Feng, H., Zhuang, S., Liu, Z., Zhu, T., Ye, K., Xing, Y., Sun, C., Zhou, F., et al. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0670-6 · Cited by 69
Cosman, F. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0596 · Cited by 71
Self-citationWei, Y., Peng, C., Wang, S., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab240 · Cited by 64
Osteoporosis in 2022: Care gaps to screening and personalised medicine
Curtis, E. M., Dennison, E. M., Cooper, C. C., & Harvey, N. C. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101754 · Cited by 74
“Whilst DXA screening is officially a standard policy in the US (at the age of 65 years in women, and age 70 in men, and in individuals over the age of 50 years who have suffered an adult fracture) (59), in the majority of countries, primary prevention is focused more on opportunistic case-finding, triggered by the pre…”
BackgroundManagement of osteoporosis in patients with chronic kidney disease
Abdalbary, M., Sobh, M., Elnagar, S., Elhadedy, M. A., Elshabrawy, N. A., Abdelsalam, M., Asadipooya, K., Sabry, A. A.-A., Halawa, A. M., & El-Husseini, A. A. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06462-3 · Cited by 79
“On the other hand, VFA has some advantages, i.e., less radiation exposure, lower costs, and greater patient convenience, because it can be performed at the same time as BMD measurements [63].”
BackgroundInfluentialPostmenopausal Osteoporosis: A Literature Review
Bhatnagar, A., & Kekatpure, A. L. (2022) · Cureus · doi:10.7759/cureus.29367 · Cited by 105
“It fails to acknowledge the dosage and duration of the uses of glucocorticoids [88], and it only scores the BMD of the femoral neck and does not take into account other sites, such as the lumbar vertebrae [85].”
BackgroundHu, Y., Tang, Y., Zhang, Z., et al. (2023) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2023.108634 · Cited by 64
Classification of Osteoporosis
Amarnath, S. S., Kumar, V., & Das, L. (2023) · Indian Journal of Orthopaedics · doi:10.1007/s43465-023-01058-3 · Cited by 93
“The treat-ment for osteoporosis is indicated when the FRAX 10-year probability of a hip fracture is ≥ 3% or the risk for a major osteoporosis-related fracture is ≥ 20%[15].”
Hansen, A. E., Obel, N., Nielsen, H. I., Pedersen, C. D., & Gerstoft, J. (2010) · HIV Medicine · doi:10.1111/j.1468-1293.2010.00864.x · Cited by 70
Al‐Saleh, Y., Sulimani, R. A., Sabico, S., Raef, H., Fouda, M. A., Alshahrani, F., Shaker, M., Wahabi, B. A., Sadat‐Ali, M., Rayes, H. A., et al. (2015) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2015.1 · Cited by 68
Extensive undertreatment of osteoporosis in older Swedish women
Lorentzon, M., Nilsson, A. G., Johansson, H., Kanis, J. A., Mellström, D., & Sundh, D. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04872-4 · Cited by 64
Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis
Raterman, H. G., Bultink, I. E. M., & Lems, W. F. (2019) · Drugs · doi:10.1007/s40265-019-01145-6 · Cited by 65
Fracture risk assessment by the FRAX model
McCloskey, E. V., Harvey, N. C., Johansson, H., Lorentzon, M., Liu, E., Vandenput, L., Leslie, W. D., & Kanis, J. А. (2021) · Climacteric · doi:10.1080/13697137.2021.1945027 · Cited by 71
Harahap, I. A., & Suliburska, J. (2021) · Foods · doi:10.3390/foods10112685 · Cited by 70
“However, pharmacological agents such as bisphosphonates, calcitonin, and denosumab (a receptor activator of nuclear factorκB ligand / RANKL inhibitor) are not prescribed for long-term use, frequently require regular infusion appointments, and carry their own risk of adverse drug responses [12].”
BackgroundBone regeneration in osteoporosis: opportunities and challenges
Patel, D., & Wairkar, S. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01222-6 · Cited by 76
“NCT00500409 Safety and efficacy of OSTEOFORM (rhPTH [1-34]) in increasing bone mineral density in osteoporosis Osteoporosis Osteoform, Shelcal 3 428 Drug Delivery and Translational Research (2023) 13:419–432”
BackgroundWalter, N., Szymski, D., Kurtz, S. M., et al. (2023) · Bone and Joint Research · doi:10.1302/2046-3758.122.bjr-2022-0275.r1 · Cited by 63
Tissue-selective estrogen complexes for postmenopausal women
Mirkin, S., & Komm, B. S. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.06.003 · Cited by 68
Diagnosis and Treatment of Osteoporosis: What Orthopaedic Surgeons Need to Know
Matzkin, E. G., DeMaio, M., Charles, J. F., & Franklin, C. C. (2019) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-18-00600 · Cited by 69
A Review on the Role of Denosumab in Fracture Prevention
Pang, K.-L., Low, N. Y., & Chin, K. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s270829 · Cited by 72
Improved prediction of fracture risk leveraging a genome-wide polygenic risk score
Lu, T., Forgetta, V., Keller‐Baruch, J., Nethander, M., Bennett, D., Forest, M., Bhatnagar, S., Walters, R. G., Lin, K., Chen, Z., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00838-6 · Cited by 70
Filipović, T., Lazovic, M. P., BACKOVIĆ, A. N., Filipović, A., Ignjatović, A., Dimitrijević, S., & Gopčević, K. (2021) · European Journal of Physical and Rehabilitation Medicine · doi:10.23736/s1973-9087.20.06149-3 · Cited by 80
The “Three in One” Bone Repair Strategy for Osteoporotic Fractures
Chen, X., Hu, Y., Geng, Z., & Su, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.910602 · Cited by 71
“The average daily intake of elemental calcium in the elderly population is approximately 400 mg, and still need an additional supplementation of about 600 mg calcium carbonate and calcium citrate (26).”
BackgroundIki, M., Fujita, Y., Tamaki, J., Kouda, K., Yura, A., Sato, Y., Moon, J., Winzenrieth, R., Okamoto, N., & Kurumatani, N. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3092-3 · Cited by 64
Osteoporosis: a clinical and pharmacological update
Vidal, M., Thibodaux, R. J., Neira, L. F. V., & Messina, O. D. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4370-1 · Cited by 67
Nayak, S., & Greenspan, S. L. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3437 · Cited by 66
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.